Secondary adrenal insufficiency: from the physiopathology to the possible role of modified-release hydrocortisone treatment
The DOI matches its Crossref record.
Abstract
Central adrenal insufficiency (AI) represents a life-threatening disorder that results from a reduced cortisol production due to an impairment production of adrenocorticotropic hormone (ACTH). In particular, secondary AI results from pituitary disease that impedes the release of ACTH, while tertiary AI is caused from an impaired synthesis of corticotropin-releasing hormone. Central AI has an estimated prevalence of 150-280 per million, resulting more common than primary AI. Prompt diagnosis and management of this condition is crucial, but the diagnostic investigation can often be challenging, in particular in cases of recent onset of secondary adrenal insufficiency. Moreover, different formulations of steroid replacement therapy are available for both primary and central adrenal insufficiency, but the therapy of choice for the treatment of secondary hypoadrenalism is still debated. In particular, several data confirm the advantages of dual-release hydrocortisone formulation in primary hypoadrenalism, while data for secondary AI are still lacking. However, in spite of few clinical data, the use of dual release hydrocortisone can be extremely favorable in ACTH deficiency, which is associated with an increase of overall and cardiovascular mortality, also due to the risk of overtreatment. In this condition, the use of a modified-release glucocorticoid formulation, which has been demonstrated to improve metabolic profile, can be extremely attractive.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The measurement of the total daily amount of cortisol production has been demonstrated to be around 5.7–7.4 mg/m2/day or 9.5–9.9 mg/day, supporting the utility of a therapeutic regime with oral daily hydrocortisone doses (15–25 mg/day) lower than thought in the past [24].”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [24]
In the citing paper
“The choice of the most appropriate test for the assessment of HPA axis alterations remains largely debated and, for each test, different cut-offs have been reported with different degrees of sensitivity and specificity [24].”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [24]
Citations
Cites
Still being checked.
Cited by
Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis
Paragliola, R. M., Papi, G., Pontecorvi, A., & Corsello, S. M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102201 · Cited by 181
“The choice of the most appropriate test for the assessment of HPA axis alterations remains largely debated and, for each test, different cut-offs have been reported with different degrees of sensitivity and specificity [24].”
BackgroundInfluentialSelf-citationBone safety of dual-release hydrocortisone in patients with hypopituitarism
Frara, S., Chiloiro, S., Porcelli, T., Giampietro, A., Mazziotti, G., Marinis, L. D., & Giustina, A. (2018) · Endocrine · doi:10.1007/s12020-017-1512-1 · Cited by 40
Glycometabolic Alterations in Secondary Adrenal Insufficiency: Does Replacement Therapy Play a Role?
Graziadio, C., Hasenmajer, V., Venneri, M. A., Gianfrilli, D., Isidori, A. M., & Sbardella, E. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00434 · Cited by 24
Bitencourt, M. R., Batista, R. L., Biscotto, I. P., & Carvalho, L. R. S. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000493 · Cited by 16
Pathophysiological mechanisms of fatigue and multidisciplinary management strategies (Review)
Zhou, H., Yu, W., Lei, J., Chang, R., Cheng, Y., Wang, G., & Lin, L. (2026) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2026.13086 · Cited by 10
Metadata
- Authors
- Paragliola, R. M., & Corsello, S. M.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- Venue
- Minerva Endocrinology
- Publisher
- Edizioni Minerva Medica
- Published
- 2018-05
- Volume
- 43
- Issue
- 2
- Pages
- 183-197
- ISSN
- 0391-1977 (ISSN-L)
- 2724-6507
- 2724-6116
- OpenAlex
- W2953797681
- Cited by
- 23
- References
- 0
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 2 · 2019: 1 · 2018: 4
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Minerva Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- secondary adrenal insufficiency, ACTH deficiency, cortisol, steroid replacement therapy, pituitary disorders, corticotropin-releasing factor, overtreatment, cardiovascular mortality, metabolic profile
- MeSH terms
- Adrenal Insufficiency, Adrenocorticotropic Hormone, Delayed-Action Preparations, Humans, Hydrocortisone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Secondary adrenal insufficiency: from the physiopathology to the possible role of modified-release hydrocortisone treatment. https://app.cochat.ai/papers/10.23736/s0391-1977.17.02701-8
- The paper
- Paragliola, R. M., & Corsello, S. M. (2018). Secondary adrenal insufficiency: from the physiopathology to the possible role of modified-release hydrocortisone treatment. Minerva Endocrinology. https://doi.org/10.23736/s0391-1977.17.02701-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.